HK1202062A1 - Dual inhibitor of met and vegf for treating cancer - Google Patents

Dual inhibitor of met and vegf for treating cancer Download PDF

Info

Publication number
HK1202062A1
HK1202062A1 HK15102604.7A HK15102604A HK1202062A1 HK 1202062 A1 HK1202062 A1 HK 1202062A1 HK 15102604 A HK15102604 A HK 15102604A HK 1202062 A1 HK1202062 A1 HK 1202062A1
Authority
HK
Hong Kong
Prior art keywords
vegf
met
treating cancer
dual inhibitor
cancer
Prior art date
Application number
HK15102604.7A
Other languages
English (en)
Chinese (zh)
Inventor
Dana T AFTAB
Frauke Schimmoller
Original Assignee
Exelixis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis, Inc. filed Critical Exelixis, Inc.
Publication of HK1202062A1 publication Critical patent/HK1202062A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
HK15102604.7A 2011-11-08 2012-11-08 Dual inhibitor of met and vegf for treating cancer HK1202062A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161557358P 2011-11-08 2011-11-08
US61/557,358 2011-11-08
PCT/US2012/064116 WO2013070890A1 (en) 2011-11-08 2012-11-08 Dual inhibitor of met and vegf for treating cancer

Publications (1)

Publication Number Publication Date
HK1202062A1 true HK1202062A1 (en) 2015-09-18

Family

ID=47179011

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102604.7A HK1202062A1 (en) 2011-11-08 2012-11-08 Dual inhibitor of met and vegf for treating cancer

Country Status (15)

Country Link
US (1) US20140323522A1 (enExample)
EP (1) EP2776033A1 (enExample)
JP (2) JP2014532766A (enExample)
KR (1) KR20140088610A (enExample)
CN (1) CN104159585A (enExample)
AU (2) AU2012335737A1 (enExample)
BR (1) BR112014011009A2 (enExample)
CA (1) CA2854336A1 (enExample)
EA (1) EA201490944A1 (enExample)
HK (1) HK1202062A1 (enExample)
IL (1) IL232421A0 (enExample)
IN (1) IN2014CN04067A (enExample)
MX (1) MX2014005458A (enExample)
TW (2) TW201818937A (enExample)
WO (1) WO2013070890A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
JP6158705B2 (ja) 2010-09-27 2017-07-05 エクセリクシス， インク． 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
KR20210147117A (ko) 2011-02-10 2021-12-06 엑셀리시스, 인코포레이티드 퀴놀린 화합물들의 제조 방법들 및 상기 화합물들을 함유하는 약학 조성물들
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
GEP201706678B (en) 2011-05-02 2017-06-12 Exelixis Inc Method of treating cancer and bone cancer
CA2848512A1 (en) 2011-09-22 2013-03-28 Exelixis, Inc. Method for treating osteoporosis
MX343288B (es) 2011-10-20 2016-11-01 Exelixis Inc Proceso para la preparación de derivados de quinolina.
EP2844254A1 (en) * 2012-05-02 2015-03-11 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
BR112015023109A2 (pt) 2013-03-15 2018-05-15 Exelixis Inc Metabolitos de n-(4-{[6,7-bis(metiloxi)quinoloin-4-il] oxi}fenil)-n -(4-fluorofenil)ciclopropano-1, 1- dicarboxamida
ES2927651T3 (es) 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
US9149471B2 (en) * 2013-09-30 2015-10-06 National University Corporation Tokyo University Of Agriculture And Technology Therapeutic agent for osteoporosis
UA123534C2 (uk) 2014-02-14 2021-04-21 Екселіксис, Інк. Кристалічні тверді форми n-{4-[(6,7-диметоксихінолін-4-іл)окси]феніл}-n'-(4-флуорофеніл)циклопропан-1,1-дикарбоксаміду, способи отримання і способи застосування
JP6666849B2 (ja) 2014-03-17 2020-03-18 エグゼリクシス， インコーポレイテッド カボザンチニブ製剤の投与
CN104788372B (zh) * 2014-07-25 2018-01-30 上海圣考医药科技有限公司 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
CN106715397B (zh) 2014-07-31 2021-07-23 埃克塞里艾克西斯公司 制备氟-18标记的卡博替尼及其类似物的方法
AU2015301097B2 (en) 2014-08-05 2021-03-04 Exelixis, Inc. Drug combinations to treat multiple myeloma
CN105503717A (zh) * 2014-09-24 2016-04-20 江苏奥赛康药业股份有限公司 一种苹果酸卡博替尼化合物及其药物组合物
CN109069499A (zh) * 2016-04-15 2018-12-21 埃克塞里艾克西斯公司 使用 n-(4-(6,7-二甲氧基喹啉-4-基氧基)苯基)-n’-(4-氟苯基)环丙烷-1,1-二甲酰胺,(2s)-羟基丁二酸盐治疗肾细胞癌的方法
CA3040788C (en) * 2016-10-18 2022-01-11 Beijing Konruns Pharmaceutical Co., Ltd. Quinolyl-substituted carboxylic acid compound or pharmaceutically acceptable salt thereof, pharmaceutical composition of the same, and use of the same
CN110621662B (zh) 2017-05-26 2023-06-23 埃克塞里艾克西斯公司 一种盐的结晶性固体形式、制备工艺和使用方法
US11542259B2 (en) 2018-01-26 2023-01-03 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
CN116808044A (zh) 2018-06-15 2023-09-29 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
KR20250136810A (ko) 2023-01-31 2025-09-16 한다 온콜로지, 엘엘씨 개선된 카보잔티닙 조성물 및 사용 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ES2436888T3 (es) 2003-09-26 2014-01-07 Exelixis, Inc Moduladores c-Met y métodos de uso
WO2008083319A1 (en) 2006-12-29 2008-07-10 Il Yang Pharmaceutical Company, Ltd. Solid state forms of enantiopure ilaprazole
UA108618C2 (uk) * 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
JP6158705B2 (ja) * 2010-09-27 2017-07-05 エクセリクシス， インク． 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
CA2812744A1 (en) * 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases

Also Published As

Publication number Publication date
TW201818937A (zh) 2018-06-01
TW201322981A (zh) 2013-06-16
US20140323522A1 (en) 2014-10-30
IN2014CN04067A (enExample) 2015-10-23
CA2854336A1 (en) 2013-05-16
IL232421A0 (en) 2014-06-30
EA201490944A1 (ru) 2014-10-30
TWI662962B (zh) 2019-06-21
CN104159585A (zh) 2014-11-19
EP2776033A1 (en) 2014-09-17
KR20140088610A (ko) 2014-07-10
BR112014011009A2 (pt) 2017-06-06
AU2017225103A1 (en) 2017-09-28
AU2012335737A1 (en) 2014-06-05
WO2013070890A1 (en) 2013-05-16
JP2018048154A (ja) 2018-03-29
JP2014532766A (ja) 2014-12-08
MX2014005458A (es) 2015-04-16

Similar Documents

Publication Publication Date Title
HK1202062A1 (en) Dual inhibitor of met and vegf for treating cancer
HK1207587A1 (en) A dual met - vegf modulator for treating osteolytic bone metastases
MX2013003594A (es) Inhibidores dobles de met y factor de crecimiento endotelial vascular (vegf) para el tratamiento de cancer de prostata resistente a la castracion y metastasis de osteoblasticas en los huesosl.
IL279330A (en) Combined treatment including antibodies against Claudin 18.2 for the treatment of cancer
IL276434A (en) Combined treatment involving antibodies against claudin 18.2 for the treatment of cancer
WO2013056148A3 (en) Scd1 antagonists for treating cancer
PH12013502623A1 (en) Metalloenzyme inhibitor compounds
PH12013502622A1 (en) Metalloenzyme inhibitor compounds
PH12013502624A1 (en) Metalloenzyme inhibitor compounds
WO2011133875A3 (en) Metalloenzyme inhibitor compounds
WO2012064943A3 (en) Metalloenzyme inhibitor compounds
HK1212221A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
ZA201300762B (en) Novel combination therapy for the treatment of cancer
PL3254695T3 (pl) Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu
WO2012058529A3 (en) Metalloenzyme inhibitor compounds
WO2012082746A3 (en) Metalloenzyme inhibitor compounds
WO2012106473A8 (en) Dosing for treatment with anti-egfl7 antibodies
AP2011005893A0 (en) Thia-triaza-cyclopentazulenes as P13-kinases inhibitors for the treatment of cancer.
WO2013070933A3 (en) Compositions and methods for the treatment of prostate carcinoma
HK1187832A (en) Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
HK1187831A (en) Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
HK1185283A (en) Combination therapy for the treatment of prostate carcinoma